NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
Clinical Trials
10 trialsNCT01652976 2021-01-05
FOLFOX-D
University of Florida
Phase 2 Completed
NCT02428855 2020-07-31
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00568750 2019-06-17
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
Swiss Cancer Institute
Phase 2 Completed
NCT00464620 2018-11-23
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00459108 2018-04-19
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01234935 2018-01-09
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Translational Oncology Research International
Phase 2 Completed
NCT01395017 2016-04-08
LAPC
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2 Completed
NCT00474812 2015-05-05
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00504153 2014-05-19
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed